Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

Diabetes isn't just costing Indians their lifelong savings, it's also costing the country INT11.4 trillion.

According to a Nature Medicine study, India faces the second highest economic burden due to this chronic condition. Only the United States ranks higher, with costs touching INT 16.5 trillion, while China comes in third at INT 11 trillion.

While excluding informal care provided by family members, the global costs comes around INT 10 trillion which is about 0.2 per cent of the world’s annual gross domestic product (GDP).

However, if informal care is factored in, costs goes up to INT152 trillion or 1.7 per cent of the world’s yearly GDP, as per the study. (An international dollar, or INT$, is a statistical unit that has the same purchasing power as a US dollar).

The scientists estimated that the economic impact of diabetes was much more than Alzheimer’s disease or cancer in the top three countries.

The Diabetes Crisis In India

Diabetes is a chronic condition affecting several aspects of physical and mental health. It occurs when either the body can’t make enough insulin or can’t use it effectively, which impairs several functions.

Often referred to as the 'Diabetes capital of the world', over 100 million people across India suffer from the chronic condition while another 136 million are living with prediabetes.

According to Pharmeasy 2025 Diabetes Report, one in two people show high blood sugar levels when tested and over 90 percent of reports with high blood sugar also showed abnormality in one or the other parameters for liver, lipid, heart or thyroid issues.

Also known as a 'Silent Killer', diabetes can develop and progress quietly in the body, often without clear or early symptoms. Multiple studies show that over 50 percent of people with diabetes in India are undiagnosed or unaware of their condition.

When left undiagnosed and untreated, diabetes can cause severe complications across the body including heart disease, kidney damage or vision loss. These complications disproportionately affect vulnerable parts of the population, especially those in rural areas without access to proper testing and treatment.

Despite the growing economic burden, India faces systemic challenges in addressing diabetes, including inadequate healthcare infrastructure, low public awareness and fragmented policy responses.

What Did The Study Find?

They evaluated costs based on medical expenses, productivity losses and caregiving.

While the burden in the US is largely due to high treatment costs and loss of physical capital, the high costs are mainly driven by the sheer number of people affected in India and China, the researchers said.

Author Klaus Prettner, professor of macroeconomics and digitalization at the Vienna University of Economics and Business noted of the results: "Caregivers often drop out of the labor market, at least partially, which creates additional economic costs."

"This is a stark illustration of how medical treatment regimes for chronic diseases such as diabetes are accessible to high income countries only," co-author Michael Kuhn, acting economic frontiers research group leader at the International Institute for Applied Systems Analysis, added.

Based on the results, the scientists said promoting healthier lifestyle, regular physical activity and a balanced diet is the most effective way to prevent diabetes and reduce its economic impact in each country in the long run.

Colleen Hoover, the best-selling author of 'Regretting You' and 'Verity', has revealed that she has undergone treatment for cancer.

On January 12, Hoover announced via her Instagram Stories that she has one more day of radiation left at Texas Oncology.

"Second to last day of radiation," she captioned the post on her Instagram Stories. "I wish I could blame my hair and facial expressions on @Texas.Oncology, but they've been great. Hope you never need them, but highly recommend them."

In December 2025, the 46-year-old writer wrote on her Facebook page that she had been diagnosed with cancer and had undergone surgery. The film producer also noted that she would only need radiation, but not chemotherapy as a treatment plan.

Hoover said she had been in Canada filming Reminds of Him when she noticed she “had recurring health issues that I continued to put off until the movie was finished" and a check-up revealed that she had developed cancer.

What Kind Of Cancer Does She Have?

While she is yet to reveal which kind of cancer she is receiving treatment for, Hoover has confirmed it was not caused by family genes, HPV or excessive hormones.

In a Facebook post from January 9, she noted that the reason for her illness is 'more than likely' to be environmental/lifestyle, which can be credited to a lack of exercise, poor diet and stress.

"I’m happy and grateful to be alive but I hate vegetables. I hate when I have to get off the couch. I hate sweating. I hate when science is right. If you see me at the gym, don’t even tell me good job. If you see me at a restaurant eating grilled chicken and drinking water, I’m probably real mad about it," she wrote in a heartfelt moment.

Why Has Hoover Been Missing From Public Eye?

Hoover's health updates and cancer treatment come amid a series of cancelled public events. In October 2025, she announced she would not attend the premiere of Regretting You, her latest movie adaptation.

In a sentimental Instagram post, she told her fans: "I’m super bummed, but am having an unavoidable surgery and can’t travel for a while,” Hoover wrote in her Instagram post at the time. I’ll live vicariously through you guys. So sad to miss this movie release and premiere, but so grateful to all the actors and the team who put this together.”

Woman Down is Hoover’s next book release set for January 13. However, the author has had to tell fans that a book-signing tour has not been set up yet and she will not be meeting with the public for now.

“I wanted to make this post and be transparent about why that is. I’m not saying I won’t be up to doing at least one signing, but I just won’t know until I know," she said.

Meanwhile, throughout 2025, production on her hit novel, Verity, has begun in 2025, with Anne Hathaway and Josh Hartnett, being photographed during scenes last February. Additionally, her third movie adaptation, Reminders of Him, is also set to hit theaters on March 13, 2026.

It remains unknown if she will be attending the premiere for Reminders of Him.

Barbie. A name too familiar for everyone growing up, now Mattel Studio has launched its first autistic Barbie. This is after Greta Gerwig's 2023 blockbuster movie that introduced the concept of diverse characters of Barbie, that Mattel launched its first Barbie with type 1 diabetes. The studio is definite about creating a diverse range of Barbie character, as an animated Barbie film too is in the development.

Why Is The Launch Of Autistic Barbie Important?

Autistic Barbie is the latest addition to Barbie's Fashionistas range, which is designed so more children can "see themselves in Barbie". The Barbie is created in collaboration with the US charity the Autistic Self Advocacy Network. The Barbie is designed to represent the ways autistic children may have experienced, including the way they communicate.

Barbie With Autism: What Are Her Features?

The Barbie's eyes gaze slightly to one side, which could represent how some autistic people avoid direct eye contact. The Barbie also comes with completely bendable elbows and wrists, which enables her repetitive physical movements such as stimming and hand-flapping that help people with autism to process sensory information, or even express excitement.

She also holds a pink fidget spinner on her finger, which helps her reduce her stress, wears noise-cancelling headphones, also in pink, to reduce sensory overload, and carries a pink tablet with symbol-based augmentative and alternative communication buttons on its screen that helps with her everyday communication.

Barbies earlier came in one-size-fit-all, often lacking the diversity and representation, this Barbie, however, wears a loose-fitting purple pinstripe A-line dress. This has minimized fabric to skin contact, and her shoes have flat soles that promotes stability and ease of movements.

Read: Hundreds Of US Children Have Type 1 Diabetes, Now Their Barbie Has It Too

Barbie's Representation Matters

The first Barbie came in 1959, and until 2019, there were no dolls with disabilities. Now, there are Barbies with diabetes, blind dolls, and Barbies with wheelchairs, Down syndrome, prosthetic limb, vitiligo, and hearing aids. There is also a Ken doll with a prosthetic leg, and another one who uses a wheelchair with a ramp, and one with hearing aids.

Jamie Cygielman, the global head of dolls at Mattel while announcing the autistic Barbie said, "Barbie has always strived to reflect the world kids see and the possibilities they imagine, and we’re proud to introduce our first autistic Barbie as part of that ongoing work. The doll helps to expand what inclusion looks like in the toy aisle and beyond because every child deserves to see themselves in Barbie."

She also added: “We engaged with the autistic community throughout the design process, always mindful that autism is experienced differently by every individual and is not always visible. The elements of this doll reflect how some people on the spectrum may experience and express the world, and we hope that by partnering with influential voices within the community, Barbie can continue to showcase a broader range of authentic experiences.”

What Is Autism?

As per the American Psychiatric Association, ASD is a complex developmental condition involving persistent challenges with social communication, restricted interests and repetitive behavior. While autism is considered a lifelong condition, the need for services and supports because of these challenges varies among individuals with autism.

As per the Centers for Disease Control and Prevention, an estimated one in 36 children have been identified with ASD.